Notícias Incyte Corporation - INCY | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Incyte Corporation (INCY)
Incyte Corporation (INCY) Notícias

Incyte Corporation (INCY)

71,91

2,28

(3,27%)

Fechado 06 Janeiro 6:00PM

Atrasado por 15 minutos

71,91

0,00

(0,00%)

Após o horário de negociação: 9:46PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Incyte to Present at Upcoming Investor Conference

Form 144 - Report of proposed sale of securities

Aktuelle Incyte Tafasitamab (Monjuvi® ) Daten demonstrieren auf dem ASH 2024 deutlich verbessertes progressionsfreies Überleben bei Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom

Les données de dernières minutes d'Incyte sur le tafasitamab (Monjuvi®) à l'ASH 2024 démontrent une survie sensiblement améliorée de la survie sans progression chez les patients atteints de lymphome folliculaire récidivant ou réfractaire

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições